Videos

Alice J Chen, PhD, found that delays affected access to CAR-T treatments and treatment effectiveness among patients with refractory and relapsed aggressive blood cancer.

Vikas Mehta, MD, MPH, proposes instituting time to treatment initiation as an oncology, site-specific quality measure, looking at time from diagnosis to first treatment, and establishing metrics around that time point as a means to improve...

Tycel Phillips, MD, reviews standard therapies utilized for patients with mantle cell lymphoma, including nonaggressive regimens and BTK inhibitor therapies.

Kerry Rogers, MD, discusses a retrospective cohort study looking at depth of response and progression-free survival outcomes among patients with chronic lymphocytic leukemia treated with ibrutinib.

Winston Wong, PharmD, discusses results from the IKEMA trial, a randomized, open-label, multicenter phase 3 study comparing isatuximab plus carfilzomib and dexamethasone vs carfilzomib and dexamethasone in patients with relapsed multiple...

Gordon Kuntz sits down with Ira Klein, MD, MBA, to discuss the need for industry standards in next-generation sequencing and comprehensive genomic profiling and how the lack of standards is impacting patients, providers, and payers.

Debra Patt, MD, MPH, MBA, implemented digital health solutions across a large practice, aiming to better understand which patient populations use these tools over time and characterize engagement across populations to enhance clinical...

Brian Reid, Head of Corporate Pricing and Public Affairs at Real Chemistry, offers insight on the Inflation Reduction Act and the impact it may have on the way that pharmaceuticals are marketed, priced, and sold, as well as its aims to reform...

Kerry Rogers, MD, led a study analyzing tumor lysis syndrome (TLS)-associated health care resource utilization and costs among patients with chronic lymphocytic leukemia and small lymphocytic lymphoma who were treated with regimens associated...

Debra Patt, MD, MPH, MBA, investigated utilization among patients with cancer who enrolled in a portfolio of digital health solutions (DHS), aiming to understand how utilization of oncology DHS may be limited among certain populations.